Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Synchron

company

About

Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.

Details

Last Funding Type
Series C
Last Funding Money Raised
$75M
Industries
Computer,Information Technology,Manufacturing,Marketing,Medical,Medical Device
Founded date
Apr 1, 2016
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
Synchron, Inc.

Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$200M
Synchron has raised a total of $200M in funding over 2 rounds. Their latest funding was raised on Dec 16, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 16, 2022 Series C $75M 1 ARCH Venture Partners Detail
Dec 15, 2022 Series C $75M 17 ARCH Venture Partners Detail
Feb 4, 2022 Funding Round 1 Max Hodak Detail
Jun 3, 2021 Series B $40M 12 Khosla Ventures Detail
Apr 4, 2017 Series A $10M 2 Neurotechnology Investors Detail

Investors

Number of Lead Investors
Number of Investors
5
22
Synchron is funded by 22 investors. ARCH Venture Partners and Max Hodak are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Yes Series C
Max Hodak Yes Funding Round
Alumni Ventures Series C
Bezos Expeditions Series C
Forepont Capital Partners Series C
Gates Frontier fund Series C
General Advance Series C
Greenoaks Series C
ID8 Investments Series C
Khosla Ventures Series C

Employee Profiles

Number of Employee Profiles
7
Synchron has 7 current employee profiles, including Board member Robert Nelsen
Board member
Executive
Executive
Employee
Board member